|Articles|March 4, 2020

How is the US Tracking Coronavirus Contacts?

A CDC report contains details on the public health efforts being employed to track contacts of people with COVID-19.

As the US Centers for Disease Control and Prevention (CDC) prepares for more cases of novel coronavirus (COVID-19) linked to community spread, active monitoring of individuals exposed to patients with confirmed COVID-19 will be essential to mitigating the impact of the virus

A new CDC Morbidity and Mortality Weekly Report article contains details on public health efforts that are being employed to track contacts of people with COVID-19. Monitoring efforts are aimed at ensuring the rapid diagnosis and care of patients, limiting further spread of the viruses, and improving clinical understanding of risk factors for transmission.

The first case of COVID-19 in the United States was diagnosed on January 20th, in Washington State.

“On January 20th, state and local health departments in the United States, in collaboration with teams deployed from CDC, began identifying and monitoring all persons considered to have had close contact with patients with confirmed COVID-19,” authors of the report wrote.

On January 31st, US Department of Health and Human Services Secretary Alex Azar signed a public health emergency declaration. Soon after, the US Food and Drug Administration (FDA) issued emergency authorization for a COVID-19 diagnostic which has not yet gone through the FDA approval process, allowing any CDC qualified lab to use the test.

As of February 26th, 12 of the COVID-19 cases diagnosed in the United States were believed to be travel related. An additional 3 cases were known at the time in patients without travel history, 2 of which were close household contacts of cases with travel history to China.

The confirmed cases were isolated in the hospital if medically necessary, or otherwise kept at home. A total of 445 contacts were monitored in connection with the first 10 patients. Of these individuals, 222 were health care professionals.

Monitoring was conducted by daily to assess possible symptoms via telephone, text, or in-person visits. The contacts of confirmed cases were monitored actively for 14 days. During this period, 54 developed symptoms which put them in the “under investigation” category and prompted testing. Of these, 2 household members of patients with COVID-19 tested positive for the virus.

The contacts of these 2 individuals were monitored. Out of 146 monitored contacts, none tested positive for COVID-19 despite 18 developing concerning symptoms which prompted testing.

However, since these early cases were monitored there have been cases which appear to point to community spread.

“Since February 28th, an increasing number of newly diagnosed confirmed and presumptive COVID-19 cases have been in patients with neither a relevant travel history nor clear epidemiologic links to other confirmed COVID-19 patients,” the authors of the report wrote.

As of March 3rd, 9 US COVID-19 associated deaths occurred among individuals in Washington state.

While individual monitoring is an important part of early containment efforts, it’s possible that as more cases are reported, the strategy of close monitoring will need to shift.

“At some point, we’re going to be shifting our approach from counting every case to focusing on outbreaks, perhaps cases that occur at hospitals, and we won’t be able to do the kind of individual case follow up and case management that we’re doing early on during this so called containment phase of the epidemic," Washington public health officer Jeff Duchin, MD, said.

For the most recent counts in the COVID-19 outbreak in the United States and abroad, visit the Contagion® Outbreak Monitor.


Related to this article

Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Measles Update: October 16, 2026
The latest CDC numbers show an 8.1% increase in measles cases from week-to-week, bringing the 2026 US total to 4410 confirmed cases. A CDC disease detective is going to Pennsylvania to aid in the state's massive outbreak, and the agency reports on a rare measles complication that is uniformly fatal.
NFID Survey Finds Respiratory Vaccine Gap Driven by Lack of Clarity, Not Hesitancy
The National Foundation for Infectious Diseases (NFID) recently held its respiratory season kick-off, which included the release of its annual respiratory disease survey. This year, the survey revealed the gap between vaccine support and uptake. Robert Hopkins Jr, MD, medical director of NFID delves deeper into the findings of the survey and the vaccine uptake challenges associated with certain immunizations.
Measles Update: October 9, 2026
The latest CDC numbers show a 5.0% increase of measles cases from week-to-week. The US total reached 4080 confirmed cases, 78% above all of 2025.